Illumina
ILMN
$160.97
-3.15%
Illumina Inc. is a global leader in the healthcare sector, specifically within the Medical - Diagnostics & Research industry, providing tools and services for genetic analysis. The company is the dominant market leader in DNA sequencing technology, generating over 90% of its revenue from sequencing instruments, consumables, and services, which are foundational for research, clinical diagnostics, and personalized medicine. The current investor narrative is intensely focused on the company's strategic path following its acquisition and subsequent divestiture of Grail, with recent news highlighting the high-risk, high-reward debate around Grail's cancer detection test, while the core business aims to return to consistent growth and margin expansion after a period of financial volatility.…
ILMN
Illumina
$160.97
Related headlines
Investment Opinion: Should I buy ILMN Today?
Rating & Thesis: Hold. Illumina is a high-quality company in a powerful technical uptrend, but its valuation has run ahead of its near-term fundamental growth profile, creating an unfavorable risk/reward setup at current levels. The mixed institutional analyst sentiment (Buys, Holds, and an Underweight) underscores this uncertainty.
Supporting Evidence: The stock trades at a forward P/E of 28.38x, a premium to its sector, on estimated EPS of $8.84. While profitability is strong (28.8% net margin) and cash generation is excellent ($939M TTM FCF), revenue growth is only 4.98% YoY. The technical picture shows the stock is extended, trading just 5% below its 52-week high after a 102% annual gain. The high beta of 1.424 signals elevated volatility risk for new entrants at this level.
Risks & Conditions: The two biggest risks are 1) multiple compression if growth fails to accelerate, and 2) a technical reversal from overbought conditions. This Hold rating would upgrade to a Buy if the stock experiences a healthy pullback to the $130-$140 range (improving margin of safety) or if quarterly revenue growth accelerates sustainably above 8%. It would downgrade to a Sell if revenue growth turns negative or if the forward P/E expands beyond 35x without a corresponding jump in growth estimates. Relative to its history and growth profile, the stock is currently overvalued.
Sign up to view all
ILMN 12-Month Price Forecast
The assessment is neutral based on a clash between strong fundamentals and stretched valuation/technical levels. The company's quality is undeniable—return to high profitability, robust cash flow, and market leadership. However, the stock's 102% rally has priced in much of this improvement, leaving limited near-term upside without evidence of accelerating growth. The high beta suggests the path will be volatile. The stance would upgrade to bullish on a pullback to the $140-$150 range (improving risk/reward) or on consecutive quarters of revenue growth above 7%. It would turn bearish if the stock breaks below the $114 support level on deteriorating fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Illumina's 12-month outlook, with a consensus price target around $209.26 and implied upside of +30.0% versus the current price.
Average Target
$209.26
10 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
10
covering this stock
Price Range
$129 - $209
Analyst target range
Analyst coverage for Illumina appears limited based on the provided data, with only 10 analysts providing estimates for revenue and EPS. The data shows estimated EPS for the next period averaging $8.84, with a range from $8.73 to $8.96, and estimated revenue averaging $5.83 billion. However, a consensus price target, recommendation breakdown (Buy/Hold/Sell), and implied upside are not available in the provided dataset, indicating insufficient analyst coverage for a full consensus view. The implications of limited coverage are significant; it can lead to higher volatility and less efficient price discovery, as the stock may be more driven by institutional flows and news events than by a broad base of professional research. The available institutional ratings from early 2026 show a mixed but leaning positive sentiment, with firms like Guggenheim and Stifel maintaining 'Buy' ratings, while JP Morgan and TD Cowen are at 'Neutral/Hold', and Barclays is 'Underweight'. This divergence in views signals ongoing debate about the company's prospects, particularly surrounding the Grail spin-off and core business execution.
Bulls vs Bears: ILMN Investment Factors
The bullish case for Illumina is currently stronger, anchored by a powerful fundamental turnaround to strong profitability and cash generation, coupled with exceptional technical momentum. The bear case centers on valuation risk, with the stock priced for perfection after its massive rally. The single most important tension in the investment debate is whether the company's modest ~5% core revenue growth can accelerate sufficiently to justify and sustain its elevated forward P/E of 28.4x, or if the current valuation already reflects an overly optimistic growth scenario, setting the stage for disappointment.
Bullish
- Strong Return to Profitability: The company has executed a decisive turnaround, posting a robust Q4 2025 net income of $334 million, translating to a 28.8% net margin. This contrasts sharply with the massive $1.988 billion loss in Q2 2024, demonstrating effective financial restructuring post-Grail.
- Exceptional Cash Generation: Illumina is generating substantial free cash flow, with a trailing twelve-month figure of $939 million. This provides significant financial flexibility to fund R&D, strategic initiatives, and potential shareholder returns without reliance on external financing.
- Powerful Technical Momentum: The stock is up 102.09% over the past year and 34.86% over the past three months, significantly outpacing the S&P 500. It is trading at 95% of its 52-week high, indicating strong bullish conviction and a clear breakout from its previous trading range.
- High-Margin, Defensible Core Business: The company maintains a high gross margin of 67.04% (Q4 2025), underpinned by its dominant market share in sequencing consumables. This strong profitability profile provides a solid foundation for the post-Grail standalone entity.
Bearish
- Elevated Valuation Premium: The stock trades at a forward P/E of 28.38x and a P/S of 4.81x, a significant premium to many healthcare equipment peers. This leaves little room for error, as any growth deceleration could trigger a sharp multiple contraction.
- Modest Core Revenue Growth: Sequencing revenue growth is modest, with Q4 2025 revenue of $1.159 billion representing only a 4.98% year-over-year increase. This slow growth trajectory may struggle to justify the current premium valuation multiple.
- High Volatility and Beta: With a beta of 1.424, the stock is approximately 42% more volatile than the broader market. This high volatility, combined with its proximity to the 52-week high, increases the risk of a sharp pullback on any negative news.
- Limited Analyst Coverage & Sentiment Divergence: Only 10 analysts provide estimates, indicating limited coverage which can lead to inefficient price discovery. Institutional ratings are mixed (e.g., Barclays 'Underweight', JP Morgan 'Neutral'), reflecting ongoing debate about the company's post-Grail execution.
ILMN Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a 102.09% gain over the past year. As of the latest close at $168.06, the price is trading near the top of its 52-week range, approximately 95% of the way from its 52-week low of $81.76 to its high of $177.22, indicating strong momentum but also potential overextension. Recent momentum has been exceptionally strong, with the stock up 20.85% over the past month and 34.86% over the past three months, significantly outpacing the S&P 500's gains of 4.6% and 12.6% over the same periods, respectively, as shown by relative strength figures of 16.25 and 22.26. The stock's short-term momentum is accelerating and aligns with the long-term uptrend, suggesting continued bullish sentiment. The price recently surged from a low near $114 in mid-February to current levels, demonstrating a sharp recovery and breakout from a lower trading range. The stock exhibits high volatility, with a beta of 1.424, meaning it is approximately 42% more volatile than the broader market, which investors must factor into risk management and position sizing. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $177.22 and support at the recent swing low area near $114.44 from February. A decisive breakout above $177.22 would signal a continuation of the bullish trend and potentially target new highs, while a breakdown below the $114 support could indicate a significant trend reversal. The stock's high beta of 1.424 confirms its status as a high-volatility name, prone to larger swings than the overall market.
Beta
1.49
1.49x market volatility
Max Drawdown
-25.7%
Largest decline past year
52-Week Range
$86-$177
Price range past year
Annual Return
+82.7%
Cumulative gain past year
| Period | ILMN Return | S&P 500 |
|---|---|---|
| 1m | +11.0% | -0.1% |
| 3m | +35.3% | +12.0% |
| 6m | +19.4% | +8.8% |
| 1y | +82.7% | +22.9% |
| ytd | +19.8% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ILMN Fundamental Analysis
Revenue growth has been modest but positive, with Q4 2025 revenue of $1.159 billion representing a 4.98% year-over-year increase. Segment data reveals the core Sequencing business, at $1.065 billion, is the primary driver, while the legacy Microarray segment contributed $94 million. The multi-quarter trend shows revenue has grown sequentially from $1.041 billion in Q1 to the current level, indicating a steady, albeit slow, recovery trajectory from prior periods of stagnation. The company has returned to profitability with a strong Q4 net income of $334 million, translating to a net margin of 28.8%. Gross margins are robust at 67.04% for the quarter, consistent with the company's high-margin consumables business model. The operating margin for the quarter was 22.09%, showing effective cost control. This represents a significant improvement from the substantial losses recorded in 2024, such as the -$1.988 billion net income in Q2 2024, marking a decisive turnaround towards sustainable profitability. The balance sheet is healthy with a current ratio of 2.08, indicating strong short-term liquidity. The debt-to-equity ratio is manageable at 0.94. Most importantly, the company is generating substantial cash, with trailing twelve-month free cash flow of $939 million, providing ample internal funding for growth initiatives, research and development, and potential shareholder returns. The return on equity of 31.22% is exceptionally high, reflecting efficient use of shareholder capital post the Grail-related financial restructuring.
Quarterly Revenue
$1.2B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.67%
Latest Quarter
Free Cash Flow
$939000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ILMN Overvalued?
Given the company's positive net income of $334 million in the latest quarter, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 24.52x, while the forward PE is 28.38x based on estimated EPS of $8.84. The higher forward multiple suggests the market is pricing in expectations for earnings growth in the coming year, though it also indicates the stock is not cheap on an earnings basis. Compared to sector averages, Illumina trades at a significant premium. Its trailing PE of 24.52x and Price-to-Sales (PS) ratio of 4.81x are elevated relative to many healthcare equipment peers, though direct industry averages are not provided in the data. This premium is likely justified by its market-leading position in a high-growth potential industry (genomic sequencing) and its return to strong profitability and cash generation, as evidenced by a 28.8% net margin and $939 million in TTM FCF. Historically, the current trailing PE of 24.52x sits above its own recent quarterly ranges observed in 2025 (e.g., 15.40x in Q4 2025, 23.89x in Q3 2025), indicating the market is currently valuing the company more optimistically. This positioning near the higher end of its recent historical band reflects renewed confidence in the post-Grail standalone story and its improved fundamental trajectory, leaving little room for disappointment.
PE
24.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -56x~2943x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is valuation compression, not balance sheet weakness. The company's healthy current ratio of 2.08 and manageable debt-to-equity of 0.94 indicate solid liquidity. However, the operational risk lies in revenue concentration and growth trajectory; over 90% of revenue comes from sequencing, and the recent 4.98% YoY growth is modest. The stock's premium valuation (28.38x forward P/E) is highly dependent on accelerating this growth. A failure to do so, or a margin miss from the current robust 28.8% net income level, could trigger significant earnings multiple de-rating.
Market & Competitive Risks: The stock faces pronounced market risk due to its high beta of 1.424, making it 42% more volatile than the market and susceptible to sharp downdrafts in a risk-off environment. Competitive risks are inherent as the dominant player in sequencing, but the more immediate threat is sector rotation away from high-multiple healthcare names if interest rates remain elevated. The stock's 102% one-year gain and proximity to its 52-week high leave it vulnerable to profit-taking, especially given the mixed institutional sentiment (e.g., Barclays' Underweight rating) which highlights ongoing skepticism about the post-Grail narrative.
Worst-Case Scenario: The worst-case scenario involves a combination of a growth scare and a broad market sell-off. Specifically, a Q3 earnings miss where revenue growth decelerates below 4% and margins contract, coupled with a sector-wide de-rating of growth stocks, could catalyze a severe correction. Given the stock's high volatility, a realistic downside could see it re-test its recent significant support level near $114.44 (the February low), representing a potential loss of approximately -32% from the current price of $168.06. A breach of that level could target the 52-week low of $81.76, though that seems less probable without a fundamental catastrophe.
FAQ
The key risks are, in order of severity: 1) Valuation Compression Risk: The high forward P/E of 28.4x is vulnerable if growth disappoints. 2) Execution Risk: The company must accelerate growth beyond the current ~5% to justify its premium. 3) High Volatility: With a beta of 1.424, the stock is prone to larger swings than the market, especially after a 102% rally. 4) Sentiment Risk: Limited analyst coverage and mixed institutional ratings (e.g., Barclays Underweight) indicate lingering skepticism that could limit upside.
The 12-month outlook presents three scenarios. The Base Case (60% probability) sees the stock trading between $150 and $180 as it consolidates recent gains, assuming steady ~5% growth. The Bull Case (25% probability) targets $185 to $210 on accelerated growth and multiple expansion. The Bear Case (15% probability) warns of a pullback to $114-$140 on growth disappointment and de-rating. The Base Case is most likely, predicated on the company maintaining, but not significantly accelerating, its current financial performance.
ILMN appears overvalued relative to its near-term growth trajectory. The stock trades at a forward P/E of 28.38x and a P/S of 4.81x, which are premiums to sector averages. This pricing implies the market expects a significant acceleration in growth from the current 4.98% YoY pace. Compared to its own history, the trailing P/E of 24.52x is at the higher end of its recent range. The valuation is fair only if robust double-digit earnings growth materializes; otherwise, it is stretched.
ILMN is a Hold, not a compelling buy at the current price. While the company has executed a remarkable turnaround to strong profitability (28.8% net margin) and is a market leader, the stock has already rallied 102% over the past year and trades at a premium forward P/E of 28.4x. This valuation leaves little margin for error given its modest 5% revenue growth. It could be a good buy for patient, long-term investors on a significant pullback (e.g., towards $140), but the current risk/reward is unfavorable for new capital.
ILMN is more suitable for a long-term investment horizon of 3+ years. Its high beta (1.424) and lack of dividend make it a poor fit for short-term trading or income seekers. The long-term thesis rests on the enduring growth of genomic sequencing, but near-term volatility is elevated. Investors should be prepared to withstand significant price swings. A minimum holding period of 18-24 months is suggested to allow the post-Grail strategy to unfold and for potential growth acceleration to materialize and be recognized by the market.